Can Autodesk and Organovo Bring Tissue Engineering to a Hospital Near You?

New light is shed on a forgotten collaboration between Autodesk and Organovo to inject predictability into the design of living systems.

Apr 22, 2014 at 6:30PM

Tissue engineering has captured the imagination of mainstream media and investors alike. In the future, will humans be able to bioprint living tissue to repair and replace ailing or diseased tissue? Could companies eventually print functional cancerous tissue in the lab to hasten the development of oncology drugs? Tissue engineering may be in its infancy today, but it could be getting closer to reality with companies such as Organovo Holdings (NYSEMKT:ONVO) developing futuristic technology platforms.

While I think investors got a little ahead of themselves with Organovo in 2013, especially considering its lengthy timeline for product revenue, I was surprised to learn the company was a leading partner with Autodesk (NASDAQ:ADSK) for a next-generation meta platform using computer-aided design for characterizing biology, or bioCAD. The collaboration was announced in January 2013, but I did not think much about it at the time. However, my recent work in the synthetic biology industry, one of the four fields targeted by the same bioCAD platform, has led me back to Organovo.

ONVO Chart

ONVO data by YCharts.

Should the collaboration change how investors think of Organovo? Heck, should investors think differently about Autodesk, which isn't traditionally associated with life sciences? I recently spoke to Carlos Olguin, head of the Bio/Nano/Programmable Matter Group at Autodesk Research, to find out more about a project - Project Cyborg - that could impact both Autodesk and Organovo.

What is Project Cyborg?
Project Cyborg is a Web-based software meta platform, or a platform that will serve as a foundation for more specialized platforms, that aims to more effectively characterize biology and nano-matter. If successful, engineers will be capable of accurately designing virtual living systems -- and finding fatal flaws in their designs -- before creating a physical real-world prototype. That would drastically reduce the time and money spent on an inefficient design cycle for producing organisms and biological systems.

Think about it: Today, designers and engineers can use Autodesk software to create, manipulate, simulate, model, and optimize virtual macro objects ranging from bicycles, to skyscrapers, to entire cities in amazing detail before a single aluminum frame is built or slab of concrete is poured. Engineers can test how a new airplane design will react to real-life conditions at an altitude of 36,000 feet before shoving a pilot in the cockpit and slamming the door. Can you imagine creating thousands of airplane prototypes, performing tests to collect data, and then calibrating the final results for each plane before having a marketable product? Maybe not, but that's exactly how we design biology today.


Source: Autodesk.

What makes that level of efficiency possible for macro objects? We understand macro systems and how changing variables will affect how physical objects interact with their environment. We have equations that can accurately model these interactions as each variable is altered. Unfortunately, the same is not true for smaller, more complex systems, such as a living cell. There are many interdependent variables that affect living systems, which makes it nearly impossible to get enough predictability with biology (given our current understanding). For instance, changing the temperature in a bioreactor or bioprinter by several degrees can affect cell division (affecting contamination probability), protein folding (affecting enzyme functionality), feedstock uptake (affecting time to product), dissolved oxygen content (affecting cell growth), and, ultimately, the products created by cells (affecting margins), among other variables.

Suddenly, accurately studying how temperature affects your system doesn't seem so easy, especially if you have to conduct each run in the real world in real time. The goal of Project Cyborg is to create a software tool for researchers and engineers to design biology virtually in much the same way an architect can build a house or an engineer a plane. By creating more accurate models, Autodesk and Organovo will increase the predictability of their systems and reduce the number of prototypes needed to achieve a final design.

What can Project Cyborg do for Organovo?
Well, almost exactly what is described above. Autodesk and Organovo are working together to make tissue engineering, or 3-D bioprinting, more accurate and predictable. Despite the hype surrounding Organovo's capabilities, it is important to understand that the tissues currently created by the NovoGen bioprinter are only several cell layers thick. Building larger models for toxicology testing would, presumably, lead to more accurate results and allow tissues to survive even longer than 40 days -- increasing the value to the pharmaceutical industry and selling price of each. But the number of iterations needed to go from a tissue several cell layers thick to one many times larger (that retains functionality) would require a terrifying lengthy process if conducted solely with real-world prototypes. Forget having a complete organ ready for transplantation with that design cycle.


The NovoGen bioprinter, and future iterations of the hardware, could disrupt the health care industry in profound ways. Source: Organovo.

Autodesk and Organovo are tackling the problem from several unique angles. First, the pair is integrating hardware (3-D bioprinters) into Project Cyborg to enable an end-to-end platform. That will smooth out any errors from the current fragmented approach that takes data from software and hardware that do not communicate with each other. Second, the collaborators are removing the labor-intensive laboratory steps with automated solutions. It is still a distant reality, but it is not impossible to think that a future fabrication facility for human tissues would operate almost entirely autonomously. A server could receive a request from a hospital or clinic for a tissue type, a liquid-handling robot could fetch reagents to feed to the 3-D bioprinters, and a functional made-to-order tissue could come out on the other end -- reducing overhead and in-house requirements for human scientists. Finally, what better way to learn what you don't know than attempt to model it with software? Researchers will discover which relationships they don't understand, attempt to understand them, and then integrate the interaction into the software platform.

Foolish takeaway
I believe the collaboration between Autodesk and Organovo will be necessary to create larger fully functional tissues on a timeline that satisfies investors and with accuracy that satisfies regulatory guidelines. It does not justify a lofty valuation for Organovo just yet, nor does it guarantee success. But the way I look at it, someone is going to figure out how to predictably characterize biology for tissue engineering applications eventually. Organovo seems to have the head start necessary to allow for successful platform development, and investors should not take for granted a future-focused collaboration with an industry leader such as Autodesk. Nonetheless, I'll stick to my previous opinion and remain on the sidelines until more meaningful product development and revenue becomes apparent.

3 stocks poised to be multi-baggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Maxx Chatsko has no position in any stocks mentioned. Autodesk has sponsored past SynBioBeta events and conferences. Check out his personal portfolioCAPS pageprevious writing for The Motley Fool, or his work for SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers